MedTrace Logo

Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria

NCT07559370 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1116

Last updated 2026-06-29

No results posted yet for this study

Summary

This study is investigating an innovative approach to treating uncomplicated malaria by adding a drug called Imatinib to the current standard of care, Artemether + Lumefantrine (AL). The researchers hope this combination, known as ALIM, will clear infections faster and stop the spread of drug-resistant parasites that are becoming a major threat in Africa

Conditions

  • Malaria (Plasmodium Falciparum)

Interventions

DRUG

Artemether lumefantrine tablets

There is no difference

DRUG

Artemether Lumefantrine and Imatinib Mesylate

There is no difference

Sponsors & Collaborators

  • Purdue University

    collaborator OTHER

  • Victoria Biomedical Research Institute

    lead OTHER

Principal Investigators

  • Dr. Quentin Awori MBChB · Victoria Biomedical Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-20
Primary Completion
2027-06-30
Completion
2027-06-30

Countries

  • Kenya

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07559370 on ClinicalTrials.gov